The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The three pathways were given in random order: The trial completed recruitment in 2020 ... Our study can influence future treatment guidelines for DPNP, but also chronic neuropathic pain treatment in ...

We study the hypothesis according to which plasticity in pain signaling and modulating pathways contributes to long-lasting neuropathic pain, which is a common clinical problem. We study plasticity of ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...